Coral Springs, FL (PRWEB)
July 26, 2017
CNA Finance Chief Research Analyst, Kenny Soulstring, today announced that the stock market news outlet had initiated coverage on Aytu Bioscience and sees significant upside potential based on a de-risked product pipeline and an established and producing commercialization strategy.
According to Soulstring, Aytu Bioscience is continuing to demonstrate substantial success in bringing novel urology based treatments to market. The company has seen consistent sales growth in core products, highlighted by a compounded 20% growth in unit sales during the previous six months. Aytu is expected to continue to drive sales momentum and has guided toward additional growth and momentum from its core products.
Additional and near-term revenue opportunity is also expected to spike from sales of other products in the pipeline portfolio. ProstaScint and MiOXSYS each have either FDA approval or a CE marking designation and are globally positioned to deliver substantial revenue in the next twelve months. MiOXSYS is focused on a $4.7 billion market. ProstaScint, also an approved for the market product, is focused on diagnostic testing for prostate cancer, a $7 billion market in 2016 that is expected to grow significantly over the next five years. Finally, Soulstring believes that Aytu’s interest in expanding their focus into additional and related markets will also drive consumer interest and therefore contribute to increased demand.
Importantly, because of Aytu’s commercialization placements, Soulstring believes that much of the product pipeline is already de-risked from both FDA and European regulatory agencies. Additionally, because of the niche based product placements, the company may be in a prime position to deliver simultaneous and accretive revenue generating…